SEQUENCE LISTING

<110> ALNYLAM PHARMACEUTICALS, INC. et al.

<120> METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) IRNA COMPOSITIONS

<130> 121301-07020

<140>
<141>

<150> 62/435,127
<151> 2016-12-16

<160> 31

<170> PatentIn version 3.5

<210> 1
<211> 938
<212> DNA
<213> Homo sapiens

<400> 1
gttgactaag tcaataatca gaatcagcag gtttgcagtc agattggcag ggataagcag 60

cctagctcag gagaagtgag tataaaagcc ccaggctggg agcagccatc acagaagtcc 120

actcattctt ggcaggatgg cttctcatcg tctgctcctc ctctgccttg ctggactggt 180

atttgtgtct gaggctggcc ctacgggcac cggtgaatcc aagtgtcctc tgatggtcaa 240

agttctagat gctgtccgag gcagtcctgc catcaatgtg gccgtgcatg tgttcagaaa 300

ggctgctgat gacacctggg agccatttgc ctctgggaaa accagtgagt ctggagagct 360

gcatgggctc acaactgagg aggaatttgt agaagggata tacaaagtgg aaatagacac 420

caaatcttac tggaaggcac ttggcatctc cccattccat gagcatgcag aggtggtatt 480

cacagccaac gactccggcc cccgccgcta caccattgcc gccctgctga gcccctactc 540

ctattccacc acggctgtcg tcaccaatcc caaggaatga gggacttctc ctccagtgga 600

cctgaaggac gagggatggg atttcatgta accaagagta ttccattttt actaaagcag 660

tgttttcacc tcatatgcta tgttagaagt ccaggcagag acaataaaac attcctgtga 720

aaggcacttt tcattccact ttaacttgat tttttaaatt cccttattgt cccttccaaa 780

aaaaagagaa tcaaaatttt acaaagaatc aaaggaattc tagaaagtat ctgggcagaa 840

cgctaggaga gatccaaatt tccattgtct tgcaagcaaa gcacgtatta aatatgatct 900

gcagccatta aaaagacaca ttctgtaaaa aaaaaaaa 938

<210> 2
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 2
ugggauuuca uguaaccaag a 21

<210> 3
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 3
ucuugguuac augaaauccc auc 23

<210> 4
<211> 23
<212> DNA
<213> Homo sapiens

<400> 4
gatgggattt catgtaacca aga 23

<210> 5
<211> 650
<212> DNA
<213> Homo sapiens

<400> 5
acagaagtcc actcattctt ggcaggatgg cttctcatcg tctgctcctc ctctgccttg 60

ctggactggt atttgtgtct gaggctggcc ctacgggcac cggtgaatcc aagtgtcctc 120

tgatggtcaa agttctagat gctgtccgag gcagtcctgc catcaatgtg gccgtgcatg 180

tgttcagaaa ggctgctgat gacacctggg agccatttgc ctctgggaaa accagtgagt 240

ctggagagct gcatgggctc acaactgagg aggaatttgt agaagggata tacaaagtgg 300

aaatagacac caaatcttac tggaaggcac ttggcatctc cccattccat gagcatgcag 360

aggtggtatt cacagccaac gactccggcc cccgccgcta caccattgcc gccctgctga 420

gcccctactc ctattccacc acggctgtcg tcaccaatcc caaggaatga gggacttctc 480

ctccagtgga cctgaaggac gagggatggg atttcatgta accaagagta ttccattttt 540

actaaagcag tgttttcacc tcatatgcta tgttagaagt ccaggcagag acaataaaac 600

attcctgtga aaggcacttt tcattccaaa aaaaaaaaaa aaaaaaaaaa 650

<210> 6
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 6
ucuugguuac augaaauccc auc 23

<210> 7
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 7
ucuugguuac augaaauccc auc 23

<210> 8
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 8
ucuugguuac augaaauccc auc 23

<210> 9
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 9
ucuugguuac augaaauccc auc 23

<210> 10
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 10
ugggauuuca uguaaccaag a 21

<210> 11
<211> 16
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown:
RFGF peptide

<400> 11
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
1 5 10 15

<210> 12
<211> 11
<212> PRT
<213> Unknown

<220>
<223> Description of Unknown:
RFGF analogue peptide

<400> 12
Ala Ala Leu Leu Pro Val Leu Leu Ala Ala Pro
1 5 10

<210> 13
<211> 13
<212> PRT
<213> Human immunodeficiency virus

<400> 13
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln
1 5 10

<210> 14
<211> 16
<212> PRT
<213> Drosophila sp.

<400> 14
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 15
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 15
ugggauuuca uguaaccaag a 21

<210> 16
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 16
ugggauuuca uguaaccaag a 21

<210> 17
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 17
ugggauuuca uguaaccaag a 21

<210> 18
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide

<400> 18
ugggauuuca tguaacaaag a 21

<210> 19
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19
ugggauuuca uguaaccaag a 21

<210> 20
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide

<400> 20
ugggauuuca tguaacaaag a 21

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
oligonucleotide

<400> 21
ugggauuuca tguaacaaga 20

<210> 22
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 22
ugggauuuca uguaaccaag a 21

<210> 23
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 23
ucuugguuac augaaauccc auc 23

<210> 24
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 24
ucuugguuac augaaauccc auc 23

<210> 25
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 25
ucuugguuac augaaauccc auc 23

<210> 26
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 26
ucuugguuac augaaauccc auc 23

<210> 27
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 27
ucuugguuac augaaauccc auc 23

<210> 28
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 28
ucuugguuac augaaauccc auc 23

<210> 29
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 29
ucuugguuac augaaauccc auc 23

<210> 30
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 30
ucuugguuac augaaauccc auc 23

<210> 31
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 31
ucuugguuac augaaauccc auc 23